13F filing recap · Q1 2025

What did Fairfax Financial Holdings buy in Q1 2025?

Reported stock-position changes between this filing and the previous one.

Stock value

$1.84B

Positions

Estimated turnover

4.7%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

Quarter in review

Fairfax Financial Holdings opened a new position in Lifeway Foods and exited Revance Therapeutics, TFI International, and Xeris Biopharma Holdings. It sharply increased its Cleveland-Cliffs stake, while slightly adding to Kraft Heinz and Molson Coors Beverage. The firm also trimmed Colliers International Group and KKR.

New positions

LWAYLifeway Foods, Inc.$424.6Kreported value+17.4K shares

Increased positions

CLFCleveland-Cliffs Inc.$122.47Mreported value+9.00M shares+152.6%KHCKraft Heinz Co$102.18Mreported value+45.0K shares+1.4%TAPMolson Coors Beverage Co$73.46Mreported value+20.0K shares+1.7%

Reduced positions

CIGIColliers International Group Inc.$2.59Mreported value-3.0K shares-12.0%KKRKkr & Co. Inc.$2.31Mreported value-3.5K shares-14.9%

Exited positions

TFIITfi International Inc.$1.79Mprior reported value-13.3K shares-100.0%XERSXeris Biopharma Holdings, Inc.$472.1Kprior reported value-139.7K shares-100.0%RVNCRevance Therapeutics Inc$64.1Kprior reported value-21.2K shares-100.0%